These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 37662491)

  • 1. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands.
    Kamali AN; Bautista JM; Eisenhut M; Hamedifar H
    Ther Adv Vaccines Immunother; 2023; 11():25151355231192043. PubMed ID: 37662491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.
    Kamali AN; Hamedifar H; Eisenhut M; Bautista JM
    Ther Adv Vaccines Immunother; 2024; 12():25151355241288453. PubMed ID: 39399301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
    Lee JB; Ha SJ; Kim HR
    Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
    Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
    Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer natural products targeting immune checkpoint protein network.
    Chun KS; Kim DH; Raut PK; Surh YJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Next generation of anti-immune checkpoints antibodies].
    Bonnefoy N; Olive D; Vanhove B
    Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
    Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
    Front Oncol; 2022; 12():844260. PubMed ID: 35433470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.
    Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
    Wang L; Bai L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.
    Kuzevanova A; Apanovich N; Mansorunov D; Korotaeva A; Karpukhin A
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in TIGIT Immune-Checkpoint Role in Cancer.
    Annese T; Tamma R; Ribatti D
    Front Oncol; 2022; 12():871085. PubMed ID: 35656508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
    Saleh R; Toor SM; Sasidharan Nair V; Elkord E
    Front Immunol; 2020; 11():1469. PubMed ID: 32760400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy.
    Zhou X; Khan S; Huang D; Li L
    Front Immunol; 2022; 13():938470. PubMed ID: 36189222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
    Torphy RJ; Schulick RD; Zhu Y
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8
    Okoye IS; Houghton M; Tyrrell L; Barakat K; Elahi S
    Front Immunol; 2017; 8():1215. PubMed ID: 29033936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.